Zobrazeno 1 - 6
of 6
pro vyhledávání: ''
Autor:
Douglas Grossman, Scott R. Florell, Kenneth M. Boucher, Matthew Honeggar, Tong Liu, Pamela B. Cassidy, Sancy A. Leachman
Publikováno v:
Cancer Prevention Research. 10:36-44
Oxidative stress plays a role in UV-induced melanoma, which may arise from melanocytic nevi. We investigated whether oral administration of the antioxidant N-acetylcysteine (NAC) could protect nevi from oxidative stress in vivo in the setting of acut
Autor:
Robert Orlando, Kevin M. Huang, Rhye-Samuel Kanassatega, Bradley T. Andresen, Mandy Liu, Ying Huang, Steven Yeung, Edwin K. Jackson, Arvind Thakkar, Andy Chang, Cyrus Parsa
Publikováno v:
Cancer Prevention Research. 8:27-36
The stress-related catecholamine hormones and the α- and β-adrenergic receptors (α- and β-AR) may affect carcinogenesis. The β-AR GRK/β-arrestin biased agonist carvedilol can induce β-AR–mediated transactivation of the EGFR. The initial purp
Autor:
Chinthalapally V. Rao, Naveena B. Janakiram, Rebekah L. Ritchie, Vernon E. Steele, Altaf Mohammed, Stan Lightfoot, Laura Biddick, Venkateshwar Madka, Jagan M.R. Patlolla, Misty Brewer, Michael Sadeghi
Publikováno v:
Cancer Prevention Research. 7:1198-1209
Ornithine decarboxylase (ODC) is the key rate-limiting enzyme in the polyamine synthesis pathway and it is overexpressed in a variety of cancers. We found that polyamine synthesis and modulation of ODC signaling occurs at early stages of pancreatic p
Autor:
Michael Pollak, Carolyn Algire, Olga Moiseeva, Elena Birman, Luca A. Petruccelli, Gerardo Ferbeyre, Benoit Viollet, Lilian Amrein, Xavier Deschênes-Simard
Publikováno v:
Cancer Prevention Research. 5:536-543
Pharmacoepidemiologic studies provide evidence that use of metformin, a drug commonly prescribed for type II diabetes, is associated with a substantial reduction in cancer risk. Experimental models show that metformin inhibits the growth of certain n
Publikováno v:
Cancer Prevention Research. 4:779-782
The rexinoid bexarotene represses cyclin D1 by causing its proteasomal degradation. The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib represses cyclin D1 via different mechanisms. We conducted a preclinical study a
Autor:
Melissa L. Bondy, Katherine S. Hale, Kim Anh Do, Aysegul A. Sahin, Abenaa M. Brewster, Patricia A. Thompson, Gordon B. Mills, Caimiao Wei
Publikováno v:
Cancer Prevention Research. 5:B84-B84
Background: Gene mutations in the PI3K pathway in breast tumors are associated with resistance to tamoxifen and poorer prognosis. Differences in host susceptibility to developing breast cancers with PI3K pathway mutations may explain the heterogeneit